Relugolix and Escitalopram: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Escitalopram
Relugolix
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Both of these medicines can gently affect your heart's electrical timing, something doctors call the QT interval. Escitalopram (Lexapro) is a common antidepressant, and relugolix (Orgovyx) is used to lower testosterone in prostate cancer. Taking them together can add up and, in some people, make the heartbeat's rhythm more likely to be thrown off.
This is a possible, theoretical concern rather than something guaranteed to happen. The good news is your care team can manage it easily by checking your heart tracing (an ECG) and your blood minerals like potassium and magnesium. Please don't stop either medicine on your own. Just talk with your doctor or pharmacist so they can keep an eye on things.
Effect: Additive QT interval prolongation with combined escitalopram and relugolix.
Mechanism: Both agents independently prolong the QT interval (escitalopram is a known QT-prolonging drug; androgen deprivation from relugolix may prolong QT). This is a pharmacodynamic, additive effect, not a metabolic one. Neither drug is a prodrug here.
Evidence: Theoretical; severity rated major. Onset unspecified.
Management:
- Avoid concomitant use when possible.
- Weigh benefits of ADT in patients with congenital long QT, CHF, or electrolyte abnormalities.
- Correct and avoid hypokalemia/hypomagnesemia.
- Consider periodic ECG and electrolyte monitoring.
What happens
Increased risk of QT interval prolongation
Interaction Deep Dive
When relugolix is given together with medications that prolong the QT interval, the effects on the QT interval are additive. The androgen deprivation produced by GnRH agonists and antagonists can itself lengthen the QT interval. In patients who have congenital long QT syndrome, congestive heart failure, or recurrent electrolyte disturbances, as well as those receiving drugs recognized to prolong the QT interval, weigh whether the benefits of androgen deprivation therapy such as relugolix are greater than the possible risks 1. Where feasible, do not use relugolix at the same time as QT prolonging agents. Should concurrent administration be necessary, refrain from using drugs that produce electrolyte disturbances (that is, hypokalemia or hypomagnesemia) 2, correct any electrolyte disturbances, and consider periodic monitoring of ECGs and electrolytes 1.
Why it happens (mechanism)
Additive QT interval prolongation
How to manage this interaction
Keep taking both medicines exactly as prescribed unless your care team tells you otherwise. Because each drug can affect heart rhythm, your team may take some sensible precautions.
- Your doctor may run periodic ECGs (heart tracings) and check your potassium and magnesium levels.
- Low potassium or magnesium can add to the risk, so your team may correct these if they are low.
- Your doctor will weigh the benefits against the risks, especially if you have a heart condition or known QT problems.
Tell your pharmacist or prescriber if you feel fainting, dizziness, or a fluttering or pounding heartbeat, and share any history of heart rhythm issues.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) A study assessed male patients undergoing androgen deprivation therapy (ADT) using individual case safety reports from VigiBase, the international pharmacovigilance database, and identified 184 cases of acquired long-QT syndrome (aLQTS) and/or torsades de pointes (TdP; 11% of cases fatal), along with 99 cases of sudden death linked to ADT. The majority of aLQTS/TdP cases (62%) and sudden death cases (88%) tied to ADT arose without concurrent use of other agents recognized to raise TdP risk; nevertheless, use of 1 drug and 2 or more drugs carrying conditional, possible, or known TdP risk was documented in a portion of aLQTS/TdP (23% or 43%) and sudden death (18% and 22%) events. The agents regarded as ADTs included abiraterone, gonadotropin-releasing hormone agonists and antagonists, nonsteroidal androgen receptor inhibitors approved for prostate cancer, and 5-alpha-reductase inhibitors approved for androgenic alopecia and prostatism. Among the 10 ADTs examined, 7 demonstrated a disproportional association (reporting odds ratio, 1.4 to 4.7) with aLQTS, TdP, or sudden death, namely leuprorelin, goserelin, triptorelin, degarelix, bicalutamide, finasteride, and dutasteride. The patients had a median age of roughly 76 years, and the median time from onset to aLQTS/TdP events was 170 days (range, 7 to 4884 days), while for sudden death events it was 92 days (range, 0.25 to 4984 days). Patients were primarily on ADT for prostate cancer treatment, with some receiving it for prostatism and androgenic alopecia. The majority of patients were on ADT monotherapy (83%); 17% were on ADT combination therapy 3.
Common questions
Can I take Relugolix and Escitalopram together?
Escitalopram and relugolix can both prolong the QT interval, so taken together the risk adds up. Keep taking both as prescribed and let your care team monitor your ECG and electrolytes. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Relugolix and Escitalopram interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Relugolix and Escitalopram interaction managed?
Keep taking both medicines exactly as prescribed unless your care team tells you otherwise. Because each drug can affect heart rhythm, your team may take some sensible precautions. Your doctor may run periodic ECGs (heart tracings) and check your potassium and magnesium levels. Low potassium or magnesium can add to the risk, so your team may correct these if they are low. Your doctor will weigh th… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Relugolix or Escitalopram need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (3)
- Product Information: ORGOVYX oral tablets, relugolix oral tablets. Sumitomo Pharma America, Inc (per FDA), Marlborough, MA, 2025. DailyMed
- Lyon AR, Lopez-Fernandez T, Couch LS, et al: 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022; 43(41):4229-4361.
- Salem JE, Yang T, Moslehi JJ, et al: Androgenic effects on ventricular repolarization: a translational study from the international pharmacovigilance database to iPSC-cardiomyocytes. Circulation 2019; 140(13):1070-1080. PubMed
Keep reading about Escitalopram
Keep reading about Relugolix
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist